Skip to content
primarysourced Photonics sector GF
GFS
~8 min read · 1,829 words ·updated 2026-04-29 · confidence 33%

Capital returns — buybacks, dividends, share count

As of: 2026-04-29 (data through FY2025 20-F filed 2026-02-27 + Form 4 archive through 2026-04-27)

Confidence legend: ✓ verified-primary 20-F · ◐ partial / aggregator · ⚠ inferred / estimate

1. The headline change — first formal buyback authorization in company history

FY25 20-F verbatim: “In February 2026, we announced that our Board of Directors approved a share repurchase authorization of up to $500 million of our ordinary shares. The authorization is valid for an initial period of 12 months and may be modified, suspended or terminated at any time. Our repurchase program does not require us to repurchase any specific dollar amount or to acquire any specific number of ordinary shares. We cannot guarantee that the program will be fully consummated or that it will enhance long-term stockholder value.”

This is a structurally new development for GFS. From the 2021 IPO through FY2024, the company did not have a public-equity buyback program. The 2025 cash-generation inflection ($1.157B adjusted FCF) created the cash war chest; the deleveraging completion (Term Loan A paid down) freed up capital allocation; and the CHIPS Direct Funding restrictive covenants (which constrain dividends and repurchases) had to be negotiated to allow the program.

Authorization parameters:

  • Up to $500M of ordinary shares
  • 12-month initial period (subject to extension/modification)
  • No mandatory minimum
  • Method discretion: open market, accelerated share repurchase (ASR), 10b5-1 plans, privately negotiated

Implied capital-return capacity:

  • $500M / $33.1B market cap = 1.5% of market cap (versus, for comparison, MRVL’s $5.0B / $133B = 3.8% of market cap and AVGO’s typical 2-3% annual return)
  • $500M / $1.157B FY25 adjusted FCF = 43% of FCF — meaningful but well within free-cash-flow generation
  • Implied buy pace: $40M/month if executed evenly over 12 months; or up-front-loaded if ASR-structured

Strategic read. A $500M / 12-month authorization is modest by mature-foundry standards (TSMC has a continuous repurchase program; UMC pays a substantial dividend). It is best read as a first calibration step — testing the legal framework against the CHIPS covenant restrictions, building an investor-relations track record, before scaling to a more permanent program. Watch for renewal/expansion in February 2027 (12 months out).

2. No dividend program

GFS does not pay a dividend. Per FY25 20-F: dividend declarations are restricted by the CHIPS Direct Funding Agreement (which constrains certain capital actions while milestone disbursements are pending) and by term-loan covenants historically.

Path to dividend initiation would require:

  1. CHIPS milestone disbursement runway (i.e., disbursement substantially complete, removing covenant overhangs)
  2. Sustained adjusted FCF coverage
  3. Mubadala-driven shift in capital-return preference (Mubadala has historically prioritized growth investment via GFS over capital returns)

Analyst probability: Low for FY26-FY27. Possible by FY28-FY29 if the buyback program is renewed and expanded.

3. Share count progression — modest growth from IPO to today

DateTotal ordinary shares outstanding (M)Source
2021-10-28 (IPO)525M ⚠ ($2.6B IPO @ $47/sh on 55M secondary tranche; total post-IPO O/S ~525M) ◐F-1 prospectus + 424B4
2022-12-31~545M ⚠est. from FY22 weighted-avg shares
2023-12-31~552MFY23 20-F basic weighted-avg
2024-12-31~553MFY24 20-F basic weighted-avg
2025-12-31~555.8MComputed from Mubadala 81.0% = 450,387,613 ✓
2026-Q1 (guide)560M (fully diluted)Q1’26 6-K guidance

Total share-count growth IPO → FY25 YE: ~525M → ~556M = +31M / +6% over 4+ years. This is disciplined dilution — net share-count growth of ~7M/year (~1.3% annual) reflecting RSU/PSU vesting net of withholding and SBC reabsorption.

4. Mubadala stake trajectory

DateMubadala beneficial ownershipShares held (M)Source
Pre-IPO (Oct 2021)~89-90% (post-IPO immediate)~470MF-1 prospectus + 424B4
2022-12-31~89.4% ⚠~487Mest.
2023-12-31~89.4% (Schedule 13G filed Feb 2023)~493M13G acc. 0000315066-23-001636
2024-0586.0% ⚠ (post May 2024 secondary at ~$70)~475M ⚠424B7 acc. 0001709048-24-000039
2025-12-3181.0% ✓450,387,613 ✓FY25 20-F Item 7
2026-Q1likely ~81%~450Minferred

Mubadala selldowns since IPO:

  • IPO secondary (Oct 2021): partial Mubadala selldown
  • May 2024 follow-on offering: Mubadala selldown (per F-3ASR filed 2024-05-22 + 424B7 priced 2024-05-24); pricing at approximately $70/share, generating Mubadala estimated proceeds ~$1.0-1.5B ⚠
  • March 2026 F-3ASR shelf registration filed (acc. 0001709048-26-000028, 2026-03-11) + 424B7 priced 2026-03-12 — opens forward selldown optionality but no specific tranche announced as of 2026-04-29

The March 2026 F-3ASR is the load-bearing supply-side risk. Mubadala can now sell down on its own discretion via SEC-registered secondaries. Historical pattern: Mubadala has selldown’d in two ~$1B+ tranches in 5 years, with each tranche priced at a discount to spot — creating a structural supply overhang that depresses share-price upside.

5. Mubadala lockup / restrictions

Per the Mubadala Shareholder’s Agreement (referenced in FY25 20-F Item 7):

  • No formal lockup post-2021 IPO post-180-day restriction (which has long expired)
  • Director-nomination rights scale with ownership tier:

    • 50% ownership → majority of directors

    • 40-50% → 50% of directors
    • 30-40% → 40% of directors
    • 20-30% → 30% of directors
    • 5-20% → 20% of directors
  • Consent rights retained until Mubadala drops below specific thresholds (5% terminal threshold for Shareholder’s Agreement)
  • Audit-firm consent: Until Mubadala+Abu Dhabi government holders drop below 25%, Mubadala has consent rights on auditor selection

Practical implication: Mubadala can freely sell down to any level above 5% without Shareholder’s Agreement renegotiation. The only structural friction to a major selldown is market-impact / pricing — not contractual.

6. Stock-based compensation (SBC)

FYCost of revenue ($M)R&D ($M)SG&A ($M)Total SBC ($M)% of revenue
FY202561421022053.0%
FY20245831981872.8%
FY2023 (implied)n/dn/dn/d~$170-180 ⚠~2.4% ⚠

Source: FY2025 20-F Income Statement footnote.

SBC at 3.0% of revenue is moderate for a semiconductor capital-equipment-heavy issuer — significantly less than software/hyperscaler peers (typically 8-15%) but on the higher end for foundry peers (TSMC ~1.5%, UMC ~1.0%). The +$18M SBC increase YoY reflects normal grant-vesting and the FY25 acquisition-driven new-employee absorption.

RSUs and PSUs outstanding (per FY25 20-F):

  • 8.7M RSUs outstanding under 2021 Plan
  • 3.0M PSUs outstanding under 2021 Plan
  • 12.0M ordinary shares available for future grant
  • PSU vesting metric: Revenue + Adjusted FCF as % of Revenue + absolute TSR (Total Shareholder Return)

7. Capital-return execution mechanics

GFS’s capital-return framework is now (post Feb 2026 authorization):

  1. Operating cash flow ($1,731M FY25) →
  2. Less capex ($722M FY25) and acquisitions ($682M FY25) →
  3. Adjusted Free Cash Flow ($1,157M FY25) →
  4. Allocated to:
    • Tax payments and working-capital normalization
    • Modest debt service (interest ~$93M FY25)
    • Buyback program ($500M authorization, est. $40M/month execution rate)
    • Strategic acquisitions (M&A war chest of ~$3-4B given balance sheet capacity)
    • Net cash on balance sheet (~$2.8B net cash at FY25 YE)

Read. Capital-return at scale requires resolution of two questions: (a) does Mubadala want capital returned to all shareholders pro-rata via buybacks / dividends, or does it prefer further M&A-driven growth? and (b) when does CHIPS milestone disbursement complete sufficient milestones to free up the covenant overhang? Both questions point toward modest near-term, scalable capital-return potential through FY27-28.

8. Form 4 insider activity — light, predominantly small-volume sales

12 Form 4 filings in the period 2026-03-20 to 2026-04-27 (most recent insider archive). Net insider sentiment: mildly negative but immaterial in dollar terms.

Filers:

  • Saam Azar (CLO) — 5 sales totaling 2,500 shares for ~$120K
  • Mike Hogan (CBO) — 4 transactions (3 sales of 1,800 each + 3 gifts of 150 each)
  • Glenda Dorchak (Director) — 1 sale of 4,000 shares @ $58.46 = $233K
  • Sam Vicari (CCO) — 1 tax-withholding (Code F) of 1,461 shares

Read. All sales are <$300K in size and largely from executives doing minor portfolio diversification (not institutional-scale concerns). Hogan’s recurring $1,800-share-then-150-share-gift pattern looks like a systematic 10b5-1 plan. No large director or C-suite sales. No buys by insiders in 2026 YTD. Net insider-sentiment: neutral-to-mildly-bearish, but informationally light.

See insider history for the full Form 4 ledger detail.

9. Buyback execution outlook

At $59.49 spot (2026-04-28 close) and $500M authorization:

  • $500M / $59.49 = 8.4M shares repurchasable at current price
  • 8.4M / 555.8M = 1.5% of total shares outstanding
  • 8.4M / 83M float = 10.1% of free float — meaningful at the float level

If GFS executes the full $500M over 12 months at average price $60/share, the impact would be:

  • Reduction of free float (ex-Mubadala) by approximately 10%
  • Diluted share-count reduction of ~1.5%
  • EPS accretion of ~1.5% annualized (purely mechanical)

Tactical read. A $500M buyback executed against an 83M-share float is a structurally float-supportive capital action. If Mubadala does NOT initiate a parallel selldown in 2026, the buyback alone could shift the supply/demand dynamic favorably and contribute to share-price upside. The interaction between the F-3ASR (Mubadala selldown optionality) and the buyback authorization is the key 2026 supply-demand dynamic to monitor.

10. Open items / backfill queue

  1. Q1 2026 buyback execution — Q1’26 6-K (expected May 2026) will be the first disclosure of buyback execution under the Feb 2026 authorization. Watch for $/share, share count purchased, and remaining authorization balance.
  2. Mubadala selldown intent — no announced selldown post the 2026-03-11 F-3ASR shelf. Monitor 13D/A or 144 filings for forward selldown indication.
  3. PSU TSR-target threshold — the FY25 20-F mentions TSR-modifier-driven PSU vesting but does not disclose specific target stock prices. Expected disclosure in 2026 proxy / DEF 14A equivalent (or 6-K supplement around AGM).
  4. CHIPS-related covenant detail on dividends/repurchases — restrictive covenants are referenced but not enumerated; would clarify the post-CHIPS-disbursement capital-return capacity ceiling.

Sources

  • FY2025 20-F, acc. 0001709048-26-000022, filed 2026-02-27 — primary source for Feb 2026 buyback authorization, Mubadala 81.0% Item 7 disclosure, SBC by line item, RSU/PSU outstanding, Shareholder’s Agreement rights.
  • F-3ASR shelf registration, acc. 0001709048-26-000028, filed 2026-03-11 — opens Mubadala selldown optionality.
  • 424B7 prospectus supplement, acc. 0001709048-26-000040, filed 2026-03-12 — most recent Mubadala-attribution prospectus.
  • 2024 follow-on offering: F-3ASR acc. 0001709048-24-000029 (2024-05-22) + 424B7 acc. 0001709048-24-000039 (2024-05-24).
  • Form 4 archive (CIK 0001709048, 12 filings 2026-03-20 to 2026-04-27) — insider-transaction primary source via companies/gfs/data/insider_history.json.
  • Schedule 13G filings: FMR LLC (acc. 0000315066-24-002696, 2024-11-12 — 8.888%; subsequent FMR Schedule 13G/A No. 3 filed 2026-02-05 — 10.0% per FY25 20-F reference).

Cross-references